Watch video here > This very important question has not been answered until this research was done in Romania in 2021. The paper was not published until June 2022 although it is very relevant to potential side effects of mRNA vaccines. Read paper here >
Thanks for highlighting the paper, the issue at hand, and the wonderful open publishing platform for science!
As for the paper itself, please review the quality of the research and the writeup. That will assist the many people who are not competent to evaluate the details of statistics and research methodology, so as to avoid people sharing the paper and results inapppropriately. For example, are the results significant with only 16 samples? Why didnt they go past 15 days when the levels in blood still seemed rather high? How does this compare to the rat biodistribution study exposed from the Japan documents, or the other biodistribution study seen in the FOIA'd Pfizer submission to FDA?
E-selectin are known as “vascular selectins” because they can be expressed on endothelial cells. P-selectin is constitutively expressed by endothelial cells and platelets where they are stored in Weibel-Palade bodies and α-granules, respectively. Therefore, they can be translocated to the cell surface within minutes after a proinflammatory stimuli such as thrombin and histamine, making them the most important adhesive molecules in acute injury. On the other hand, E-selectin is not constitutively expressed by endothelial cells, but their expression is strongly upregulated by inflammatory cytokines such as interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα) through binding of NF-κB to regulatory domains in the E-selectin
Isn't this already known? And I thought it was more than 2 weeks?
More than relevant, thanks.
Thanks Dr McMillan much appreciated
Dr. Mcmillan have you seen this talk?
“Spike antigen still present as late as 60 days post-second dose”
Bret Weinstein - Robert Malone
https://youtu.be/hOxu09_JHpQ
Thank you Dr. McMillian for your ongoing investigating your valued time and sharing.
So much is being revealed for us at this time.
Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19
Excellent video and presentation of the potential mechanism of the mRNA bio distribution.
Thanks for highlighting the paper, the issue at hand, and the wonderful open publishing platform for science!
As for the paper itself, please review the quality of the research and the writeup. That will assist the many people who are not competent to evaluate the details of statistics and research methodology, so as to avoid people sharing the paper and results inapppropriately. For example, are the results significant with only 16 samples? Why didnt they go past 15 days when the levels in blood still seemed rather high? How does this compare to the rat biodistribution study exposed from the Japan documents, or the other biodistribution study seen in the FOIA'd Pfizer submission to FDA?
https://images.squarespace-cdn.com/content/v1/57d675fc46c3c43b07adb974/1657913953210-AECY8DSNOIRXVNH5Q4EZ/Zombie+Sequel+200.jpg?format=1500w
E-selectin are known as “vascular selectins” because they can be expressed on endothelial cells. P-selectin is constitutively expressed by endothelial cells and platelets where they are stored in Weibel-Palade bodies and α-granules, respectively. Therefore, they can be translocated to the cell surface within minutes after a proinflammatory stimuli such as thrombin and histamine, making them the most important adhesive molecules in acute injury. On the other hand, E-selectin is not constitutively expressed by endothelial cells, but their expression is strongly upregulated by inflammatory cytokines such as interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα) through binding of NF-κB to regulatory domains in the E-selectin
Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317703
Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
https://www.medrxiv.org/content/10.1101/2022.07.07.22277128v1